JCR’s Fabrazyme Biosimilar to Enter NHI Price List as Early as November

JCR Chairman and President Shin Ashida JCR Pharmaceuticals is poising for the NHI price listing of its biosimilar version of Sanofi’s Fabry’s disease treatment Fabrazyme (agalsidase beta) this month, Chairman and President Shin Ashida said on November 2. JCR aims...read more